Association Between Residual Viable Tumor and Prognosis After Neoadjuvant Targeted Therapy in EGFR-Mutated Non-small Cell Lung Cancer
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Age 18-80 years old;
• Pathologically diagnosed EGFR-mutated non-small cell lung cancer (NSCLC);
• Treated with neoadjuvant targeted therapy;
• Undergoing definitive surgery.
Locations
Other Locations
China
Guangdong Provincial People's Hospital
RECRUITING
Guangzhou
Contact Information
Primary
Guibin Qiao
guibinqiao@126.com
+86-13602749153
Time Frame
Start Date: 2025-02-01
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 120
Related Therapeutic Areas
Sponsors
Leads: Guangdong Provincial People's Hospital